reports about this disease condition concluded that SVCO does not constitute a radiotherapeutic emergency because there is little shown evidence that venous obstruction has caused life-threatening situations (i.e., cerebral or laryngeal edema) and the patient's demise was the direct result of SVCO. [2, 5] Furthermore, it has been observed that individuals have survived despite unrelieved blockage. Albeit the issue of PTR timing for SVCO may be contentious, we believe that treatment should not be initiated without a histological diagnosis of malignancy. Furthermore, we agree with the prevalent opinion that PTR is urgently required when stridor, cyanosis, tachypnea in an upright position in the absence of congestive heart failure, hemodynamic instability, or altered state of consciousness from cerebral edema are manifested in patients with SVCO-LCa.
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In conclusion, our retrospective study suggests that a short delay in the onset of PTR may not be harmful. Moreover, it highlights the efficacy of PTR in the alleviation of SVCO by LCa. Consensus guidelines (based on the balance of evidence from retrospective studies and expert opinion) are needed considering the fact that the disturbing acute clinical manifestations of SVCO would negate undertaking a clinical trial.
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Serum hepcidin and chronic obstructive pulmonary disease
Sir, The recent report on serum hepcidin and COPD is very interesting.
[1] Duru et al. concluded that "serum hepcidin level may be a useful marker in COPD." [1] As Duru et al. proposed, a further confirmation is required. An important point is there is no complete assessment on hepatitis profile (such as hepatitis B, hepatitis C, etc.) needed. Also, some genetic disorders can also alter the hepcidin level that has to be ruled out. Thalassemia [2] as well as some other rare genetic mutations [3] should be ruled out. It is still very inconclusive to conclude for any usefulness of hepcidin as a new biomarker for COPD.
